<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01378117</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00048954a</org_study_id>
    <nct_id>NCT01378117</nct_id>
    <nct_alias>NCT01373268</nct_alias>
  </id_info>
  <brief_title>DPP4 Inhibitor in the Hospital</brief_title>
  <official_title>Randomized Controlled Study of DPP4 Inhibitor (Sitagliptin) Therapy in the Inpatient Management of Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High blood glucose levels in hospitalized patients with diabetes are associated with
      increased risk of medical complications and death. Improved glucose control with insulin
      injections may improve clinical outcome and prevent some of the hospital complications.
      Glargine (Lantus®) insulin injection is the most common treatment of diabetes in the
      hospital. Sitagliptin (Januvia®)is effective in lowering blood glucose, but has not been
      tested in the hospital. It is not known if sitagliptin is as effective in controlling blood
      sugars in the hospital. This study will compare sitagliptin by mouth, insulin (glargine)
      injection, and the combination of sitagliptin and lantus insulin in controlling blood sugar
      in hospitalized patients with diabetes.

      In this pilot study, patients with known history of diabetes treated with diet and/or OAD or
      with low total daily dose insulin therapy (&lt;0.4 unit/kg/day) will be randomized to receive
      sitagliptin once daily (group 1), sitagliptin plus basal (glargine) insulin once daily (group
      2), or basal bolus regimen with glargine once daily and lispro insulin before meals (group
      3). If needed, patients in the 3 treatment groups will receive correction doses of
      rapid-acting lispro (Humalog®) insulin in the presence of hyperglycemia (BG &gt; 140 mg/dl) per
      sliding scale. The overall hypothesis is that treatment with sitagliptin once daily alone or
      in combination with basal insulin in patients with type 2 diabetes will result in a similar
      improvement in glycemic control and in a lower frequency of hypoglycemic events than
      treatment with basal bolus insulin regimen with glargine once daily and lispro insulin before
      meals.

      A total of 90 subjects with type 2 diabetes will be recruited in this study. Patients will be
      recruited at Grady Memorial Hospital and Emory University Hospital.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose Levels</measure>
    <time_frame>during hospitalization, average 5 days</time_frame>
    <description>The primary outcome of the study is to determine differences in glycemic control as measured by mean daily BG concentration between sitagliptin once daily and basal bolus therapy with glargine once daily plus supplemental lispro insulin in hospitalized patients with T2DM.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>during hospitalization, average 5 days</time_frame>
    <description>Number of hypoglycemic events (&lt;70 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Hypoglycemia</measure>
    <time_frame>during hospitalization, average 5 days</time_frame>
    <description>severe hypoglycemic events (&lt;40 mg/dl).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperglycemia</measure>
    <time_frame>during hospitalization, average 5 days</time_frame>
    <description>Number of episodes of hyperglycemia (BG &gt; 300 mg/dl) after the first day of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Dose of Insulin</measure>
    <time_frame>during hospitalization, average 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Need</measure>
    <time_frame>during hospitalization, average 5 days</time_frame>
    <description>Need for ICU care (transfer to ICU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Cardiac Complications</measure>
    <time_frame>during hospitalization, average 5 days</time_frame>
    <description>Cardiac complications are defined as myocardial infarction, cardiac arrhythmia requiring medical treatment, congestive heart failure, or cardiac arrest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Renal Failure</measure>
    <time_frame>during hospitalization, average 5 days</time_frame>
    <description>Acute renal failure is defined as a clinical diagnosis of acute renal failure with documented new-onset abnormal renal function (serum creatinine &gt; 2.2 mg/dL or an increment &gt; 0.5 mg/dL from baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Mortality</measure>
    <time_frame>during hospitalization, average 5 days</time_frame>
    <description>Hospital mortality. Mortality is defined as death occurring during admission</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Hospitalization</condition>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Sitagliptin + SSI prn</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin once daily plus supplemental doses of lispro if needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin and glargine+ SSI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin 50-100mg po once a day and SQ glargine insulin once daily + acqhs correctional doses of lispro if needed for elevated blood glucose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glargine and Lispro + SSI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glargine once daily and lispro before meals + acqhs supplemental insulin lispro as needed for elevated blod glucose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin 50-100mg po once daily</description>
    <arm_group_label>Sitagliptin + SSI prn</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glargine</intervention_name>
    <description>glargine once daily</description>
    <arm_group_label>Sitagliptin and glargine+ SSI</arm_group_label>
    <other_name>Lantus (glargine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lispro</intervention_name>
    <description>lispro before meals</description>
    <arm_group_label>Glargine and Lispro + SSI</arm_group_label>
    <other_name>Humalog (lispro)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females between the ages of 18 and 80 years admitted to a general medicine
             and surgery services.

          2. A known history of T2DM &gt; 3 months, receiving either diet alone, oral antidiabetic
             agents: sulfonylureas and metformin as monotherapy or in combination therapy
             (excluding TZDs and DPP4 inhibitors), or low-dose (≤ 0.4 units/kg/day) insulin
             therapy.

          3. Subjects with a BG &gt;140 mg and &lt; 400 mg/dL without laboratory evidence of diabetic
             ketoacidosis (serum bicarbonate &lt; 18 mEq/L or positive serum or urinary ketones).

        Exclusion Criteria:

          1. Age &lt; 18 or &gt; 80 years.

          2. Subjects with increased blood glucose concentration, but without a known history of
             diabetes (stress hyperglycemia).

          3. Subjects with a history of type 1 diabetes (suggested by BMI &lt; 25 requiring insulin
             therapy or with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic
             state, or ketonuria) [46].

          4. History of TZD treatment (pioglitazone or rosiglitazone) or DPP4 inhibitor
             (sitagliptin or saxagliptin) during the past 3 months prior to admission.

          5. Acute critical illness or CABG surgery expected to require prolonged admission to a
             critical care unit (ICU, CCU, SICU, neuro ICU).

          6. Subjects with gastrointestinal obstruction or adynamic ileus or those expected to
             require gastrointestinal suction.

          7. Medical or surgical patients expected to be kept NPO for &gt;24-48 hours after admission
             or after completion of surgical procedure.

          8. Patients with clinically relevant pancreatic or gallbladder disease.

          9. Patients with congestive heart failure (NYHA class III and IV), acute myocardial
             infarction, clinically significant hepatic disease or significantly impaired renal
             function (serum creatinine ≥ 2.0 mg/dL).

         10. Treatment with oral or injectable corticosteroid.

         11. Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study.

         12. Female subjects are pregnant or breast feeding at time of enrollment into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University SOM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Umpierrez GE, Gianchandani R, Smiley D, Jacobs S, Wesorick DH, Newton C, Farrokhi F, Peng L, Reyes D, Lathkar-Pradhan S, Pasquel F. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care. 2013 Nov;36(11):3430-5. doi: 10.2337/dc13-0277. Epub 2013 Jul 22.</citation>
    <PMID>23877988</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2011</study_first_submitted>
  <study_first_submitted_qc>June 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2011</study_first_posted>
  <results_first_submitted>July 9, 2013</results_first_submitted>
  <results_first_submitted_qc>June 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 12, 2014</results_first_posted>
  <last_update_submitted>June 7, 2014</last_update_submitted>
  <last_update_submitted_qc>June 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>non critical care setting</keyword>
  <keyword>hyperglycemia</keyword>
  <keyword>treatment</keyword>
  <keyword>oral antidiabetic agents</keyword>
  <keyword>subcutaneous insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>90 patients admitted to general medicine and surgeryservices in 2012 were enrolled in this pilot study. This study was conducted at Grady Memorial Hospital (Atlanta, GA), Emory University Hospital, and University of Michigan Health System.</recruitment_details>
      <pre_assignment_details>Patients were included if they had T2D with a BG 140-400 mg/dL and were treated at home with diet, oral antidiabetic agents, or low-dose insulin. Patients were excluded if in the ICU or with cardiac surgery;pancreatitis or active gallbladder disease,on steroids,significant liver disease, GFR &lt;30 or creatinine &gt;3;pregnancy, or inability to consent.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin + SSI Prn</title>
          <description>Sitagliptin once daily plus supplemental doses of lispro if needed.</description>
        </group>
        <group group_id="P2">
          <title>Sitagliptin and Glargine+ SSI</title>
          <description>Sitagliptin 50-100mg po once a day and SQ glargine insulin once daily + acqhs correctional doses of lispro if needed for elevated blood glucose</description>
        </group>
        <group group_id="P3">
          <title>Glargine and Lispro + SSI</title>
          <description>Glargine once daily and lispro before meals + acqhs supplemental insulin lispro as needed for elevated blod glucose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>discharged before med given</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin + SSI Prn</title>
          <description>Sitagliptin once daily plus supplemental doses of lispro if needed.</description>
        </group>
        <group group_id="B2">
          <title>Sitagliptin and Glargine+ SSI</title>
          <description>Sitagliptin 50-100mg po once a day and SQ glargine insulin once daily + acqhs correctional doses of lispro if needed for elevated blood glucose</description>
        </group>
        <group group_id="B3">
          <title>Glargine and Lispro + SSI</title>
          <description>Glargine once daily and lispro before meals + acqhs supplemental insulin lispro as needed for elevated blod glucose</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="11"/>
                    <measurement group_id="B2" value="58" spread="12"/>
                    <measurement group_id="B3" value="57" spread="10"/>
                    <measurement group_id="B4" value="58" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glucose Levels</title>
        <description>The primary outcome of the study is to determine differences in glycemic control as measured by mean daily BG concentration between sitagliptin once daily and basal bolus therapy with glargine once daily plus supplemental lispro insulin in hospitalized patients with T2DM.</description>
        <time_frame>during hospitalization, average 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin + SSI Prn</title>
            <description>Sitagliptin once daily plus supplemental doses of lispro if needed.</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin and Glargine+ SSI</title>
            <description>Sitagliptin 50-100mg po once a day and SQ glargine insulin once daily + acqhs correctional doses of lispro if needed for elevated blood glucose</description>
          </group>
          <group group_id="O3">
            <title>Glargine and Lispro + SSI</title>
            <description>Glargine once daily and lispro before meals + acqhs supplemental insulin lispro as needed for elevated blod glucose</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Levels</title>
          <description>The primary outcome of the study is to determine differences in glycemic control as measured by mean daily BG concentration between sitagliptin once daily and basal bolus therapy with glargine once daily plus supplemental lispro insulin in hospitalized patients with T2DM.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209" spread="67"/>
                    <measurement group_id="O2" value="203" spread="48"/>
                    <measurement group_id="O3" value="225" spread="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemia</title>
        <description>Number of hypoglycemic events (&lt;70 mg/dl)</description>
        <time_frame>during hospitalization, average 5 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Hypoglycemia</title>
        <description>severe hypoglycemic events (&lt;40 mg/dl).</description>
        <time_frame>during hospitalization, average 5 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hyperglycemia</title>
        <description>Number of episodes of hyperglycemia (BG &gt; 300 mg/dl) after the first day of treatment.</description>
        <time_frame>during hospitalization, average 5 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Dose of Insulin</title>
        <time_frame>during hospitalization, average 5 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Need</title>
        <description>Need for ICU care (transfer to ICU)</description>
        <time_frame>during hospitalization, average 5 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Cardiac Complications</title>
        <description>Cardiac complications are defined as myocardial infarction, cardiac arrhythmia requiring medical treatment, congestive heart failure, or cardiac arrest.</description>
        <time_frame>during hospitalization, average 5 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Renal Failure</title>
        <description>Acute renal failure is defined as a clinical diagnosis of acute renal failure with documented new-onset abnormal renal function (serum creatinine &gt; 2.2 mg/dL or an increment &gt; 0.5 mg/dL from baseline).</description>
        <time_frame>during hospitalization, average 5 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Mortality</title>
        <description>Hospital mortality. Mortality is defined as death occurring during admission</description>
        <time_frame>during hospitalization, average 5 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Please note that 8 patients did not receive study medication because they either withdrew or were discharged prior to receiving study medication; thus the number of participants at risk is 90-8=82 (as stated).</desc>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin + SSI Prn</title>
          <description>Sitagliptin once daily plus supplemental doses of lispro if needed.</description>
        </group>
        <group group_id="E2">
          <title>Sitagliptin and Glargine+ SSI</title>
          <description>Sitagliptin 50-100mg po once a day and SQ glargine insulin once daily + acqhs correctional doses of lispro if needed for elevated blood glucose</description>
        </group>
        <group group_id="E3">
          <title>Glargine and Lispro + SSI</title>
          <description>Glargine once daily and lispro before meals + acqhs supplemental insulin lispro as needed for elevated blod glucose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Guillermo Umpierrez, MD</name_or_title>
      <organization>EUSOM</organization>
      <phone>4047781665</phone>
      <email>geumpie@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

